Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 2, 1998, Pages 277-285

  Ichihara, Kenji ^a   Okumura, Keiichi ^a   Kamei, Hiroyuki ^a   Nagasaka, Mitsuaki ^a   Kanda, Atsuhiro ^b   Kanno, Tomohiro ^b   Miyoshi, Kazuhisa ^b   Miyake, Hidekazu ^b  

^a Maruko Pharmaceutical Co Ltd   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aranidipine; Calcium channel blocker; Diuretic effect; Metabolite; Renal hemodynamics

Indexed keywords

2 HYDROXYPROPYLMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLATE; ARANIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DRUG METABOLITE; ELECTROLYTE; NIFEDIPINE; POTASSIUM; SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG EFFECT; INTRAARTERIAL DRUG ADMINISTRATION; KIDNEY; KIDNEY BLOOD FLOW; MALE; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; URINARY EXCRETION; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CREATININE; DIHYDROPYRIDINES; DIURETICS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HYPERTENSION; INFUSIONS, INTRA-ARTERIAL; KIDNEY; MALE; NIFEDIPINE; ORGAN SIZE; P-AMINOHIPPURIC ACID; POTASSIUM; RATS; RATS, INBRED SHR; RENAL CIRCULATION; SODIUM; TIME FACTORS; TRICHLORMETHIAZIDE; URINE;

EID: 0031933423     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199802000-00014     Document Type: Article

References (59)

1. Klein W, Brandt D, Vrecko K, Härringer M. Role of calcium antagonists in the treatment of essential hypertension. Circ Res 1983;52(suppl I):174-81.
2. Reid JL, Meredith PA, Pasanisi F. Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension. J Cardiovasc Pharmacol 1985;7(suppl 4):S18-20.
3. Bühler FR, Bolli P, Erne P, et al. Position of calcium antagonists in antihypertensive therapy. J Cardiovasc Pharmacol 1985:7(suppl 4):S21-7.
4. Van Zwieten PA, Timmermans PBMWM. Pharmacological basis of the antihypertensive action of calcium entry blockers. J Cardiovasc Pharmacol 1985;7(suppl 4):S11-7.
5. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986;38:321-416.
6. Struyker-Boudier HAJ, Smits JFM, De Mey JGR. The pharmacology of calcium antagonists: a review. J Cardiovasc Pharmacol 1990;15(suppl 4):S1-10.
7. Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A. Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 1980;18:375-82.
8. DiBona GF. Renal effects of felodipine: a review of experimental evidence and clinical data. J Cardiovasc Pharmacol 1990;15(suppl 4):S29-32.
9. Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985;249:F619-29.
10. Leonetti G. The effects of calcium antagonists on electrolytes and water balance in hypertensive patients. J Cardiovasc Pharmacol 1994;24(suppl A):S25-9.
11. Abe Y, Komori T, Miura K, et al. Effects of the calcium antagonist nicardipine on renal function and renin release in dogs. J Cardiovasc Pharmacol 1983;5:254-9.
12. Kageyama M, Matsumura Y, Hayashi K, Hosokawa T, Morimoto S. Diuretic effect induced by intrarenal infusion of nisoldipine in anesthetized dogs. Clin Exp Pharmacol Physiol 1989;16:719-24.
13. Johns EJ. A study of the renal actions of amlodipine in the normotensive and spontaneously hypertensive rat. Br J Pharmacol 1988;94:311-8.
14. Kusaka H, Nomura H, Karasawa A. Effects of benidipine on renal function in anesthetized spontaneously hypertensive rats. Jpn J Pharmacol 1994;66:81-6.
15. Narita H, Nagao T, Yabana H, Yamaguchi I. Hypotensive and diuretic actions of diltiazem in spontaneously hypertensive and Wistar Kyoto rats. J Pharmacol Exp Ther 1983;472-7.
16. Nordlander M, DiBona GF, Ljung B, Yao T, Thorén P. Renal and cardiovascular effects of acute and chronic administration of felodipine to SHR. Eur J Pharmacol 1985;113:25-36.
17. DiBona GF, Sawin LL. Renal tubular site of action of felodipine. J Pharmacol Exp Ther 1984;228:420-4.
18. Larochelle P. Renal tubular effects of calcium antagonists. Kidney Int 1992;41(suppl 36):S49-53.
19. 2+ channel by MPC-1304, a novel calcium antagonist in guinea-pig hearts. Arch Int Pharmacodyn Ther 1995;330:151-64.
20. Ohashi K, Ebihara A. Aranidipine (MPC-1304), a new dihydropyridine calcium antagonist: a review of its antihypertensive action. Cardiovasc Drug Rev 1996;14:1-16.
21. Kanda A, Haruno A, Miyake H, Nagasaka M. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. J Cardiovasc Pharmacol 1992;20: 723-30.
22. 2+ entry blocker, on α-adrenoceptor-mediated pressor responses in pithed rats. Eur J Pharmacol 1993;238:283-9.
23. Kanda A, Haruno A, Miyoshi K, et al. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. J Cardiovasc Pharmacol 1993;22:167-75.
24. Miyoshi K, Kanda A, Miyake H, Ichihara K, Kamei H, Nagasaka M. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Eur J Pharmacol 1993;238:139-48.
25. Okumura K, Ichihara K, Nagasaka M, Oda N, Tajima K. Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites. Eur J Pharmacol 1993;235:69-74.
26. Miyoshi K, Miyake H, Ichihara K, Kamei H, Nagasaka M. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine. Naunvn Schmiedebergs Arch Pharmacol 1997;355:119-25.
27. Ohno S, Komatsu O, Mizukoshi K, et al. Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates with vasodilating and antihypertensive activities. Chem Pharm Bull 1986; 34:1589-606.
28. Bonsnes RW, Taussky HH. On the colorimetric determination of creatinine by the Jaffe reaction. J Biol Chem 1945;158:581-91.
29. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945;24:388-404.
30. Feigen LP, Klainer E, Chapnick BM, Kadowitz PJ. The effect of indomethacin on renal function in pentobarbital-anesthetized dogs. J Pharmacol Exp Ther 1976;198:457-63.
31. Malvin RL, Wilde WS, Sullivan LP. Localization of nephron transport by stop flow analysis. Am J Physiol 1958;194:135-42.
32. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 1963;62:351-6.
33. Romero JC, Raij L, Granger JP, Ruilope LM, Rodicio JL. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987;10:140-51.
34. Dietz JR, Davis JO, Freeman RH, Villarreal D, Echtenkamp SF. Effects of intrarenal infusion of calcium entry blockers in anesthetized dogs. Hypertension 1983;5:482-8.
35. Bell AJ, Lindner A. Effects of verapamil and nifedipine on renal function and hemodynamics in the dog. Ren Physiol 1984;7:329-43.
36. Krusell LR, Jespersen LT, Schmitz A, Thomsen K, Pedersen OL. Repetitive natriuresis and blood pressure: long-term calcium entry blockade with isradipine. Hypertension 1987;10:577-81.
37. Sterzel RB. Renal actions of calcium antagonists. J Cardiovasc Pharmacol 1987;10(suppl 10):S17-21.
38. Heller J, Horáček V. The effect of two different calcium antagonists on the glomerular haemodynamics in the dog. Pflugers Arch 1990;415:751-5.
39. Wright FS, Briggs JP. Feedback control of glomerular blood flow, pressure, and filtration rate. Physiol Rev 1979;59:958-1006.
40. Hunter M, Lopes AG, Boulpaep EL, Giebisch GH. Single channel recordings of calcium-activated potassium channels in the apical membrane of rabbit cortical collecting tubules. Proc Natl Acad Sci USA 1984;81:4237-9.
41. Wang W, Sackin H, Giebisch G. Renal potassium channels and their regulation. Annu Rev Physiol 1992;54:81-96.
42. Hebert SC, Andreoli TE. Control of NaCl transport in the thick ascending limb. Am J Physiol 1984;246:F745-56.
43. Haberle DA, Kawata T, Davis JM. The site of action of nitrendipine in the rat kidney. J Cardiovasc Pharmacol 1987;9(suppl 1):S17-23.
44. Van Hamersvelt HW, Wetzels JFM, Kloke HJ, Koene RAP, Huysmans FTM. Exogenous aldosterone antagonizes distal tubular effects of calcium entry blocker felodipine. Am J Physiol 1994; 266:F843-9.
45. Wallia R, Greenberg A, Puschett JB. Renal hemodynamic and tubular transport effects of nitrendipine. J Lab Clin Med 1985;105-498-503.
46. Giebisch G, Guckian VA, Klein-Robbenhaar G, Klein-Robbenhaar MT. Renal clearance and micropuncture studies of nisoldipine effects in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1987;9(suppl 1):S24-31.
47. Hannedouche T, Delgado A, Gnionsahe A, Lacour B, Grunfeld JP. Influence of nicardipine on renal hemodynamics and segmental tubular reabsorption of sodium in humans. J Cardiovasc Pharmacol 1989;14:856-61.
48. Martinez-Maldonado M, Cordova HR. Cellular and molecular aspects of the renal effects of diuretic agents. Kidney Int 1990;38:632-41.
49. Orloff J. Pitfalls in the use of stop-flow for the localization of diuretic action, with special reference to Na reabsorption. Ann N Y Acad Sci 1966;139:344-55.
50. Miyoshi K, Kanda A, Nozawa Y, Nakano M, Miyake H. Regional vascular effects of MPC-1304, a novel dihydropyridine derivative, in conscious normotensive and spontaneously hypertensive rats. J Pharmacol Exp Ther 1996;277:1328-36.
51. Iimura O, Shimamoto K. Efficacy and mode of action of aranidipine: a new calcium antagonist. Am Heart J 1993;125:635-41.
52. Mimran A. Antihypertensive therapy and renal function. J Cardiovasc Pharmacol 1996;27(suppl 3):S19-25.
53. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983;23:647-55.
54. Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988;8:285-90.
55. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990;37:1113-9.
56. Zucchelli P, Zuccalà A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-8.
57. Niwa M, Shigematsu K, Maeda T, et al. Effects of MPC-1304, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 1994;327:309-29.
58. Barrett RJ, Wright KF, Taylor DR, Proakis AG. Cardiovascular and renal actions of calcium channel blocker chemical subgroups: a search for renal specificity. J Pharm Pharmacol 1988; 40:408-14.
59. Weinberger MH. The relationship of sodium balance and concomitant diuretic therapy to blood pressure response with calcium channel entry blockers. Am J Med 1991;90(suppl 5A): 15S-20S.